-
公开(公告)号：US08748108B2
公开(公告)日：2014-06-10
申请号：US13311752
申请日：2011-12-06
CPC分类号： G01N33/574 , G01N33/57484
摘要： Disclosed are methods for classifying a patient with cancer as a candidate for therapy with a Bcl-2 family inhibitor comprising determining the level of at least one biomarker in a sample and comparing the biomarker level to a threshold level. Also described are methods for identifying classes of patients having a refractory cancer for second-line therapy comprising a Bcl-2 family inhibitor, where the method comprises determining the level of at least one biomarker in a sample and comparing the biomarker level to a threshold level.
摘要翻译： 公开了用于将患有癌症的患者分类为用Bcl-2家族抑制剂治疗的候选物的方法，包括确定样品中至少一种生物标志物的水平并将生物标志物水平与阈值水平进行比较。 还描述了用于鉴定包含Bcl-2家族抑制剂的用于二线治疗的难治性癌症的患者类别的方法，其中所述方法包括测定样品中至少一种生物标志物的水平并将生物标志物水平与阈值水平进行比较 。
-
2.发明申请Pro-GRP as a surrogate marker to predict and monitor response to Bcl-2 inhibitor therapy 审中-公开Pro-GRP作为预测和监测对Bcl-2抑制剂治疗反应的替代标记公开(公告)号：US20080160545A1
公开(公告)日：2008-07-03
申请号：US11647103
申请日：2006-12-28
IPC分类号： G01N33/574
CPC分类号： G01N33/574 , G01N33/57484
摘要： A method for classifying cancer patients as eligible to receive cancer therapy with a Bcl-2 inhibitor comprising determination of the presence or absence in a patient tissue sample of levels of pro-GRP, as a surrogate marker for the presence of chromosomal copy number gain at chromosomal locus 18q21-q22. The classification of cancer patients based upon pro-GRP levels as a surrogate for the presence or absence of 18q21-q22 gain allows selection of patients to receive chemotherapy with a Bcl-2 family inhibitor, either as monotherapy or as part of combination therapy, and to monitor patient response to such therapy using a peripheral blood sample.
摘要翻译： 将癌症患者分类为有资格使用Bcl-2抑制剂接受癌症治疗的方法，包括测定患者组织样品中pro-GRP水平的存在或不存在，作为染色体拷贝数增益存在的替代标记 染色体位点18q21-q22。 基于前GRP水平的癌症患者的分类作为存在或不存在18q21-q22增益的替代物允许选择患者接受Bcl-2家族抑制剂的化学疗法，作为单一疗法或作为组合疗法的一部分，以及 使用外周血样本监测患者对这种治疗的反应。
-
3.发明申请METHODS FOR PREDICTING SENSITIVITY TO TREATMENT WITH A TARGETED TYROSINE KINASE INHIBITOR 审中-公开用靶向酪氨酸激酶抑制剂预测治疗灵敏度的方法公开(公告)号：US20120190563A1
公开(公告)日：2012-07-26
申请号：US13100869
申请日：2011-05-04
IPC分类号： C40B30/04 , G01N33/567 , C40B40/10 , G01N33/566
CPC分类号： G01N33/57423 , G01N33/57484 , G01N2800/52
摘要： Methods and kits for predicting the sensitivity of a cancer to treatment with a targeted tyrosine kinase inhibitor are disclosed.
摘要翻译： 公开了用于预测癌症对靶向酪氨酸激酶抑制剂治疗的敏感性的方法和试剂盒。
-
4.发明申请PRO-GRP AS A SURROGATE MARKER TO PREDICT AND MONITOR RESPONSE TO BCL-2 INHIBITOR THERAPY 审中-公开PRO-GRP作为预测和监测对BCL-2抑制剂治疗的反应标记公开(公告)号：US20120135429A1
公开(公告)日：2012-05-31
申请号：US13309307
申请日：2011-12-01
IPC分类号： G01N33/566 , G01N21/76
CPC分类号： G01N33/574 , G01N33/57484
摘要： A method for classifying cancer patients as eligible to receive cancer therapy with a Bcl-2 inhibitor comprising determination of the presence or absence in a patient tissue sample of levels of pro-GRP, as a surrogate marker for the presence of chromosomal copy number gain at chromosomal locus 18q21-q22. The classification of cancer patients based upon pro-GRP levels as a surrogate for the presence or absence of 18q21-q22 gain allows selection of patients to receive chemotherapy with a Bcl-2 family inhibitor, either as monotherapy or as part of combination therapy, and to monitor patient response to such therapy using a peripheral blood sample.
摘要翻译： 将癌症患者分类为有资格使用Bcl-2抑制剂接受癌症治疗的方法，包括测定患者组织样品中pro-GRP水平的存在或不存在，作为染色体拷贝数增益存在的替代标记 染色体位点18q21-q22。 基于前GRP水平的癌症患者的分类作为存在或不存在18q21-q22增益的替代物允许选择患者接受Bcl-2家族抑制剂的化学疗法，作为单一疗法或作为组合疗法的一部分，以及 使用外周血样本监测患者对这种治疗的反应。
-
5.发明申请METHODS FOR PREDICTING SENSITIVITY TO TREATMENT WITH A TARGETED TYROSINE KINASE INHIBITOR 审中-公开用靶向酪氨酸激酶抑制剂预测治疗灵敏度的方法公开(公告)号：US20120115745A1
公开(公告)日：2012-05-10
申请号：US13292959
申请日：2011-11-09
申请人： Evelyn M. McKeegan , Peter Ansell , Barry L. Dowell , Ke Zhang , Viswanath Devanarayan , Arunava Charkravartty
发明人： Evelyn M. McKeegan , Peter Ansell , Barry L. Dowell , Ke Zhang , Viswanath Devanarayan , Arunava Charkravartty
IPC分类号： C40B30/04 , C40B40/10 , G01N33/566
CPC分类号： G01N33/57484 , G01N33/57423 , G01N2800/52
摘要： The present disclosure relates generally to the evaluation and/or treatment of a subject having or suspected of having a neoplastic condition, and in particular to the use of biomarkers for identifying patients receptive to a certain drug therapy, and which permit monitoring of patient response to such therapy.
摘要翻译： 本公开一般涉及具有或怀疑具有肿瘤状况的受试者的评估和/或治疗，特别是涉及使用生物标志物来鉴定接受某种药物治疗的患者，并且其允许监测患者对 这样的疗法。
-
公开(公告)号：US20080269067A1
公开(公告)日：2008-10-30
申请号：US12005688
申请日：2007-12-28
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/16
摘要： A method for classifying cancer patients as eligible to receive cancer therapy comprising determination of the presence or absence in a patient tissue sample of chromosomal copy number gain at chromosomal locus 18q21-q22. The classification of cancer patients based upon the presence or absence of 18q21-q22 gain allows selection of patients to receive chemotherapy, such as therapy with a Bcl-2 family inhibitor, and for monitoring patient response to therapy.
摘要翻译： 将癌症患者分类为符合接受癌症治疗的方法，包括确定患者组织样品中存在或不存在染色体基因座18q21-q22处染色体拷贝数增益的方法。 基于18q21-q22增益的存在或不存在，癌症患者的分类允许选择接受化疗的患者，例如用Bcl-2家族抑制剂治疗，并监测患者对治疗的反应。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.024 秒)
